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Summary
A 125-kD surface antigen of Entamoeba histolytica is recognized by 73% of immune sera from
patients with amoebic liver abscesses. Using pooled human immune sera a cDNA clone (XcM17)
encoding this antigen (M17) has been isolated from a Xgtll expression library of the virulent
stain E. histolytica HM1:IMSS. Monospecific antibodies, purified by binding to phage lysate of
AcM17, and mAb FA7 reacted exclusively with the 125-kD antigen by Western blot analysis.
Surface binding and cap formation are observed with patient sera, purified monospecific antiserum,
and mAb FA7. Corresponding genomic clones (pBSgM17-1/2/3) were isolated by hybridization
with the cDNA clone. These contained an open-reading frame of 3345 bp, which is in good
agreement with the mRNA size of -3.0 kb as revealed by Northern hybridization with AcM17.
The inferred amino acid sequence predicts a 125,513 dalton protein that contains 17 potential
Winked glycosylation sites and is unusually rich in tyrosine and asparagine residues. A distinctly
hydrophobic NHZ-terminal region may serve as membrane anchor or signal sequence. In contrast
to conservation of an immunodominant epitope recognized in pathogenic and nonpathogenic
strains by monoclonal FA7 and human immune sera, amplification and sequence analysis of a
1,400-bp fragment of this gene from a fresh nonpathogenic isolate by use ofthe PCR demonstrate
regions of significant sequence divergence in this antigen. A 1% sequence variability among
different isolates ofthe pathogenic strain HM1:IMSS and a 12-13% variability between pathogenic
and nonpathogenic strains are revealed by comparison to published partial amino acid sequences
(Tannich, E., R.D. Horstmann, J. Knobloch, and H.H. Arnold. 1989. Proc. Nad. Acad. Sci.
USA . 86:5118.). Some restriction enzymes were found that allowed PCR diagnosis ofnonpathogenic
and pathogenicisolates with the exclusion ofE. histolytica-like Laredo, suggestingthat a detailed
study of nonpathogenic and pathogenic isolates in relation to the M17 antigen sequence will
provide a basis of differentiating isolates.
E
ntamoeba histolytica is a common human pathogen that
causes a spectrum of disease ranging from a commensal
state in asymptomatic carriers to fulminant diarrhea or extra-
intestinal abscess formation. Virulent amoebae cause ulcera-
tion of the intestinalepithelium and may penetrate the bowel
wall to form extra-intestinal abscesses, primarily in the liver.
Several molecular activities thought to correlate with the viru-
lent phenotype has been partially characterized, These include
a sulfhydryl protease (1-3), a pore-forming protein (4-6), an
N-acetyl-galactosamine-specific adherence lectin (7-13), a 220-
kD N-acetyl-glucosamine lectin (14, 15), and a 96-kD sur-
face antigen (16-18); however, the role of each of these in
pathogenesis remains ill defined. Most importantly, it is still
unclear whether in a given strain invasiveness is a stable (19)
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or a variable (20-22) genotypic characteristic. Standard
methods of differentiating between potentially virulent strains
of E. histolytica include host symptomatology and serology
and the pattern of a number of parasite isoenzymes which
together constitute its zymodeme. It is this latter criterion
that has been generally used in the current classification of
E. histolytica isolates; pathogenic and nonpathogenic zymo-
demes are differentiated on the basis of polymorphisms in
the electrophoretic mobility of the glycolytic enzymes phos-
phoglucomutase (PGM),1 hexokinase (HK), and phospho-
glucoisomerase (PGI) (19, 23-26). At least 18 zymoddmms
'Abbreviations used in this paper: HK, hexokinase; PGI, phosphogluco-
isomerase; PGM, phosphoglucomutase.
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but the majority of clinical isolates fall into zymodemes I,
II, and III.
More recently several other probes, based either on DNA
sequences (27-29), or the detection ofspecific antigens (30),
have been suggested as diagnostic reagents. However, in most
cases, axenic cultivation (20) and cloning (31) of amoebae
directly from fresh stool samples before assay with any of
theseprobes have not been achieved and none ofthese probes
have been validatedby large scalescreeningofclinically defined
isolates that have also been compared with extant criteria,
such as zymodeme patterns. Since axenization and cloning
of amoebae from patient isolates appear to favor outgrowth
of the less fragile pathogenic strains andare known to result
in reversible attenuation of virulence, it is especially impor-
tant to develop probes that can directly discriminate virulent
amoebaein freshisolates. Clearly, theexistence of such probes
will be invaluable in clinically distinguishing infections caused
by a mixtureof strains or those that mayresult from pheno-
typic interconversion of pathogenic to nonpathogenic strains
as has been suggested by Mirelman (22). Presented here is
theisolationand characterization ofthe gene encoding a 125-
kD surface antigen from E. histolytica which is immuno-
dominant in patients with invasive disease. The 125-kD an-
tigenexhibits significant sequence variation among amoebal
isolates and is potentially useful in differentiatingnonpatho-
genic and pathogenic strains of E. histolytica .
Materials and Methods
Entamoeba Isolates and Cell Culture.
￿
Trophozoites of the axe-
nized E. histolytica strains (HM1:IMSS, NIH:HK9) and E. histo-
lytica-like Laredo were grown in TYI-S-33 media as described by
Diamond et al. (32) . Polyxenic isolates were grown in liquid
Robinson's medium supplemented with 10% bovine serum and
containing 5 lAg/ml of medium of each of the following antibi-
otics: kanamycin, erythromycin, and ampicillin. Amoebae were
pelleted by centrifugation at 900rpmandwashed twicewith PBS,
pH 7.5. Polyxenic amoebae were further purified by . centrifuga-
tion through aPercoll/PBS cushion at 3,000rpmin a refrigerated
Accuspin centrifuge. Isolates SD4 (pathogenic, zymodeme II) and
REF 291 and SD116(nonpathogenic, zymodemesIII and I), were
agenerous gift ofDr.Sharon Reed from theUniversity ofCalifornia,
SanDiego. Nonpathogenicisolates Nos. 43 and44 andpathogenic
isolate No. 46,classified by zymodeme analysis usinggradient PAGE
(33), were isolated in Mexico City. They correspond to Sargeaunt
zymodemes I, I, and II, respectively.
Human Immune Sera and Western Blot Analysis.
￿
Sera from 108
patients with amoebic liver abscesses were obtained from Drs. A.
Isibasi and R. Landa at theInstituto Nacional de la Nutricion and
La Raza-IMSS Hospitals, Mexico City. Diagnosis of hepatic ab-
scess in patients wasestablished by clinical symptoms, countercur-
rent immunoelectrophoresis, ELISA, and rectosigmoidoscopy. Hu-
man sera from donors without history of amoebiasis and negative
for anti-amoebic antibodies as tested by immunoblot served as con-
trols. Western blots of whole trophozoites were prepared by sus-
pendingwashed cells in PBScontaining 10 mMp-hydroxymercuri-
benzoate andLaemmli sample buffer, boiling for5 min, fractionation
by 10% or 5-15% gradient SDS-PAGE, andelectrophoretic transfer
to nitrocellulose filters. All sera were evaluated by Western blot
880
analysis on extracts of whole amoebae. 29 sera with the highest
titer were selected from the 108 samples and were pooled.
Antimembranefraction serum.
￿
This serum was obtained by im-
munizing mice with 300 l~g of membrane fraction, prepared as
described previously (34) anddiluted 1:1 with PBSand CFA. Mice
were injected intraperitoneallyevery 2 wk untiltiters reached 1:5,000
as assayed by Western blot .
mAb FA7.
￿
Whole amoebic extract from 2 x 106 amoebae
was fractionated by preparative 5-15% gradient SDS-PAGE. After
electrophoretic transfer to nitrocellulose the 125-kD region was
excised from theblot, ground to apowder, andsuspendedin PBS.
100 141 of the suspension were diluted 1:9 with PBS and injected
three times intraperitoneally into mice at 2-wk intervals with a
finalboostbefore thefusion. Hybridomas were selected by positive
reaction with the125-kD band in WesterntransfersofE. histolytica
extracts. Harvest fluid from clone FA7 was used at a 1:1,000 dilu-
tion in Western blot analysis.
Antibody Capping by Live Trophozoites.
￿
Human immune serum,
hybridomaharvest fluid from cloneFA7, and purified monospecific
antiserum, were added to live trophozoites at 1:500, 1:2,000 and
undiluted, respectively. After formationof caps (10 min at 37°C),
cells were fixed with 3.7% formaldehyde, washed with PBS, and
stained with FITC-labeled anti-human or anti-mouse IgG. Un-
diluted harvest fluid from an anti-actin-producing clone was used
as control for a nonsurface antigen (15, 35).
Preparation and Screening of Libraries.
￿
Genomic DNA and
poly(A)* RNA isolation andconstruction of the Xgt11 cDNA li-
braryfrom strain E. histolytica HM1:IMSShave been describedpre-
viously (36). For construction of the genomic library from E.
histolytica HM1:IMSS, 600,ul ofNal(GeneClean kit; Bio101)were
added to 200 IAI (x+20 jigDNA) of agarose-embedded nuclei (36)
in an Eppendorftube and melted by incubation at 60°C for5min.
20 jcl of glassmilk were added, suspended well, and the mixture
was incubated at room temperature for 5 min. The sample was
vortexed for 1 min to shear the DNA and spun in a microfuge
for 5 s. After removal of the supernatant thepellet was suspended
in 1 ml washbuffer by vortexingfor30 s. Theglassmilkwas pelleted
by a 5-s spin in the microfuge, and the supernatant was removed.
The wash was repeated twice and the sheared and purified DNA
waseluted into 100P.110 mM Tris-HCI (pH8), 1 mM EDTA (TE)
by incubation at 37°Cfor5 min. Recovery anddegree ofshearing
were assessed by agarose gel electrophoresis. All subsequent steps
includingaddition ofEcoRllinkers, methylation, ligation into the
vector XZAPII, andpackaging reaction were performedas described
previously (37, 38). TheAgt11 cDNA library (3 x 105 phage) was
screened with the pool of 29 patient sera at a 1:200 dilution (39,
40). The genomic library was screened with the cx-["P]dCTP-
labeled EcoRI fragment of XcM17. Plasmids were rescued from
genomicAZAPII clones as described previously (41). Phage DNA
and plasmid DNA were purified by standard methods (42).
Sequence Analysis.
￿
With the exception of the first 207 bp, the
entire sequence of gene M17 presented in Fig. 3 was determined
on both strands in genomic clone pBSgM17-1 and on one strand
in genomic clone pBSgM17-2. The internal EcoRI fragment
representing the cDNA insert was also sequencedon both strands
using nested deletion templates created with the PromegaBiotech
system (Madison, WI). Double-stranded sequence was also deter-
minedfortwoPCRfragmentsobtained by amplification ofgenomic
DNAfrom isolate REF 291, Zymodeme III, derived from an asymp-
tomaticCostaRicanrefugee andkindly provided by Dr. S.L. Reed.
Several oligonucleotides were used as primers in single-stranded
DNA (M13mp18/19) and double-stranded DNA [pBSKS(+)] se-
quencing reactions with the Sequenase system (U.S. Biochemical
An Immuno-dominant Variable Surface Antigen from Entamoeba histolyticaCorp., Cleveland, OH) orABI Sequencer (Applied Biosystems Inc.,
Foster City, CA) .
Primer Extension Sequence Analysis.
￿
Primer extension sequence
analysis was performed by reverse transcriptase-mediated extension
of oligonucleotide primer SR09 (5'AACTACTCCTGTGACTA-
TTGCAGAAG3') annealed to 10 Ltg poly(A) * enriched RNA in
the presence of deoxyadenosine 5'-[a-['sSlthioltriphosphate as de-
scribed previously (36) .
I-blymerase Chain Reaction .
￿
The PCR was performed using a
Cetus Corp./Perkin-Elmer DNA thermocycler. Reaction mixtures
(50 pl) contained 25 pmol ofeach ofthe two oligonucleotide primer
pairs SR018 [5'GCAACTAGTGTTAGTTATAC3'l + SR021
[5'GGTGGAATTTGGAATTCTGG3'l and SR019 [5'GTATAA-
CTAACACTAGT3'l + SR022 [5'GCTGTTACACTTGAAAA
TAT3'], x+500 ng of genomic DNA, all four dNTPs each at 1.5
mM, 60mM KCI, 25mM Tris.HCI (pH 8), 0-20 MM MgCl2,
0.1% BSA, and 10% DMSO. The reaction mixture was overlaid
with a drop of paraffin oil and denatured at 94°C for 10 min, and
amplification was initiated by addition of2.5 U of Thermus aquaticus
DNA polymerase (Cetus Corp., Emeryville, CA) . PCR parameters
were 35 thermal cycles consisting ofa 1-min denaturation of94°C
followed by a 3-min annealing period at 42°C, a 3-min ramp, and
a 4-min extension period at 72°C. The amplification products were
restricted with EcoRI and Spel endonucleases and purified for sub-
cloning into M13 by 2% low-melting-point agarose gel elec-
trophoresis .
Results
Western Blot Analysis.
￿
Sera from 108 different patients,
diagnosed with amoebic liver abscess, were each reacted with
Entamoeba whole cell extracts in Western blots ; seven antigens
(220, 190, 160, 125-129, 96, 75, 46 kD) were detected by
>62% of the sera (43) . Among these seven, a 125-kD anti-
gen wasimmunodominant, reacting strongly and being rec-
ognized by >70% of the serum samples. We assume, based
on their molecular weight and serological reactivity, that the
22041), the 160- and the 96-kD antigens represent the
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N-acetyl-glucosamine adherence lectin (14, 15), the N-acetyl-
D-galactosamine adherence lectin (7-13), and the 96-kD in-
tegral membrane protein (16-18), respectively. Because it ap-
peared that the 125-kD antigen had not been characterized,
we chose to study this immunodominant antigen in more
detail. A Western blot of whole cell extracts of axenically
or polyxenically propagated pathogenic and polyxenically
propagated nonpathogenic E. histolytica isolates was assayed
with the pooled subset of 29 human immune sera (Fig. 1) ;
the sera reacted strongly with a 125-kD antigen in all iso-
lates regardless of source . Polyspecific antiserum prepared
against amoebic plasmamembrane (34) also reacted strongly
with the 125-kD antigen (Fig . 1) . The mAb FA7, prepared
against partially purified 125-kD antigen, reacted specifically
with an epitope of the 125-kD antigen ; by Western analysis
with FA7 this epitope was detected in different strains and
species ofEntamoeba (Fig. 1) . In the Western blot with mAb
FA7 additional bands oflower molecular weight and varying
intensity are apparent in most ofthe isolates . Because potent
proteases are present in whole amoebic extracts (1-3) we as-
sume that these are degradation products of the 125-kD an-
tigen, although processing intermediates ofunknown origin
can not be ruled out .
Localization ofthe 125-kDAntigen to the Surface ofAmoebae.
Live trophozoites will cap antibody-antigen complexes bound
to their surface. Antibody-antigen caps were induced in
HMI:IMSS trophozoites by incubation with above pooled
patient serum, mAb FA7, or monospecific antibody recov-
ered after specific binding and elution of pooled patient sera
to phage lysates ofcDNA clone AcM17 (see below) (Fig . 2) ;
a negative control antibody (anti-actin mAb) neither bound
to trophozoite surfaces nor induced cap formation .
Isolation and Characterization ofacDNA Clone Encoding Part
ofthe 125-kD Antigen . The pooled sera from amoebic ab-
scess patients were used to screen a Xgt11 expression library
Figure 1 .
￿
Western blot of whole
Entamoeba extract fractionated by
5-15% SDS-PAGE, (lanes 2, 7, and
12) polyxenic pathogenic E. histo-
lytica isolate SD-4, (lanes 3, 8, and
13) polyxenic nonpathogenic E. his-
tolytica isolate SD116, (lanes 4, 9,
and 14) E. histolytica-like Laredo,
(lanes 5, 10, and 15) E. histolytica
HK-9, (lanes 6, 11, and 16) E.
histolytica HMI:IMSS probed with
anti-membrane fraction serum
(lanes 2-6), pooled human immune
sera (lanes 7-11), and mAb FA7
(lanes 12-16); molecular masses are
given in kilodaltons (molecular mass
standards lane 1 : 200, 97, 68, 43,
28 kD).from E . histolytica HMUMSS; 46 reactive clones were each
plaque purified and tested for recognition by each of the 29
patient sera included in the serum pool and by the anti-
membrane antibody. Clone AcM17 strongly reacted with 26
of 29 patient sera as well as with the anti-membrane serum .
Monospecific antibody was selected from the pooledhuman
sera by elution from filter-bound phage lysate ofXcM17 . This
eluate reacted with a single polypeptide of 125kD by Western
blot analysis ofwhole amoebic extracts ; phage lysate of4tll,
serving as negative control, did not bind antibodies reacting
with amoebic antigens (data not shown) . After nucleotide
sequence analysis, the XcM17 1.9-kb insert revealed an ORF
spanning the entire insert (Fig. 3) . The lack of a 5' initiating
methionine, the absence of a poly(A)-tail, and hybridization
to a N3 kb mRNA by Northern blot analysis (Fig . 4) in-
dicated that NH2- and COON-terminal sequences were
lacking in XcM17 .
Isolation and Characterization ofGenomic Clones Encoding the
125-kD Antigen. To isolate a genomic clone, a XZAPll li-
brary from E. histolytica HMLIMSS was screened using the
1.9-kb insert ofXcM17 as a probe. Three genomic clones were
identified, and two of these were sequenced using oligonu-
cleotide primers derived from the cDNA sequence . The
nucleotide sequence of the cDNA was identical in both
genomic clones . An additional 556 by of 5' and 870 by of
3' sequence yielded an ORF of3,345 by which was also iden-
tical in both genomic clones (Fig . 3) . The size of this ORF
(geneM17) is in reasonable agreement with themRNA size
of -3,000 by determined by Northern blot analysis (Fig . 4) .
The inferred amino acid sequence predicts a 125-kD protein .
Figure 2 .
￿
Photographs (x800) of E.
histolytica HMIJMSS trophozoites labeled in
vivo with primary antibodies . (A) Pool of
human anti-E. histolytica immune sera at
1:500 dilution ; ($) pool of human anti-E.
histolytica immune sera purified by binding to
AcM17 phage lysates ; (C) monoclonal FA7
harvest fluid at 1:1,000 dilution; (D) mono-
clonal anti-E . histolytica actin antibody at
1:1,000 dilution ; secondary antibodies, FITC
goat-anti-human and FITC goat-anti-
mouse.
5' Flanking Sequence Comparison.
￿
The 5' flanking sequence
of gene M17 shares striking similarities with the 5' flanking
region of both actin and ferredoxin genes (Fig . 5), the only
other genes ofE. histolytica where sequence has been deter-
mined . The transcriptional start site ofM17 was mapped to
an adenine residue 17by 5' of the start codon by primer ex-
tension sequence analysis using oligonucleotide SR09 (data
not shown) . 5' untranslated regions of actin (11 bp) (36, 44)
and ferredoxin (9 bp) (45) genes were likewise very short as
compared with other eukaryotic gene transcripts . A common
sequence motif, 5'ATTCA3', is present at the transcriptional
start site of bothM17 and actin genes, the initiating nucleo-
tide being an adenine residue as is most frequently found in
other eukaryotes . While the same motif is also present in
the flanking sequence of the ferredoxin gene, its cap site was
mapped to the 3' thymidine rather than the 5' adenine res-
idue (45) (Fig. 5) . An additional sequence motif sharedamong
these genes is YATTTAAA present at -29, -31, and -32 for
the M17, actin, and ferredoxin gene flanking sequences, respec-
tively. This sequence motif does not conform with the
Goldberg-Hogness promoter consensus sequence TATAAATA,
which in eukaryotic genes is located 25-30 by upstream of
the transcriptional start site . Nevertheless, this sequence is
similar in the three E. histolytica genes, both in sequence and
relative position, suggesting a consensus which inE . histolytica
serves as the entry point for RNA polymerase .
Gene CopyNumber .
￿
Southern blot and sequence analysis
of the M17 gene and limited flanking regions indicate that
this surface antigen is encoded by a single copy gene. When
a Southern blot ofgenomicDNA fromE. histolytica, restricted
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Figure 3.
￿
Inferred amino acid sequence and nucleotide sequence of coding region and flanking region obtained from genomic clone pBSgM17-1 .
The sequence o£ the internal EcoRI fragment was identical in both genomic clones (pBSgM17-1/2) and the cDNA clone XCM17 . Shown below
is the partial nucleotide sequence ofPCR amplification products derived from nonpathogenic isolate REF291 . Nucleotide substitutions are un-
derlined and amino acid substitutions are indicated below the partial sequence derived from REF291 .
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140
Asn Gly Se, Lou Gly Arg Met Pro Glu Lys Tyr Gly Gly Asp Lys Gln Phe Glu Ala Asn
AAT GGA TCA TTA GGA AGA ATG CCT GM MA TAT GGT GOT GAT MA CM TIT GM OCT MT
1261
As, Tyr Ile Leu Tyr Thr Asn Ile Al, Gly His Arg As, GI, Gly Leu Ser Gly Tcp As n
MT TAT ATT TTG TAT ACA MT ATT WT GGA CAT AGA MT CM GGA CTT AGT GOT TOG MT
MI TAT ATT CTG TAT ACG MT ATT GCA GGA CAT AGA AAA CM GGG CTT AGT GOT TOG MT
Lys
Gly Val As, Trp Glu Ala Asp Arg Lou Glu Val Arg Tyr Gly Lou Phe Gly Arg Val Phe 460
921 G GA GTT MT TWO GM WT GAT AGA TTA GM GTT AGA TAT GOT CTT
TIC
GGT AGA GTT TTT Tyr Val Ser Asp Gly Tyr Ser Th. Ile Tyr Lys Ile Leu Lys Gly Glu Asn Asp Gln Pro
180 1321 TAT GTT TCT GAT GOT TAT TCT ACA ATT TAT MA ATT CTT MA GOT GM MT GAT CM C CT
Gly Gln Arg Ala Val Ala Trp Ala Phe Pro Gly Glu Ile Val Thr Ile Lys Phe Pro Lys TAT GTT TCT GAT GO- TAT TCT ACA ATA TAT AM ATT CTT MT GOT GM MI GAT CM CCT
481 GOT CM AGA OCT GTT GCA TOG OCT TTT CCA GGA GM ATC GTT ACA ATT AM TIC CCT AAA
200 480
Gly Met Ser Tyr Lys Gly Ile Gln Val Gly Ile Gly Lys Cys As, His As, Pro Set Asp His
La
. Arg Ser Tyr Val As, Met Al. His Al. Phe Gly Thr Asp Thr La. Ile Al . Leu
541 GGA ATG AGT TAT MG GGA ATT CAG GTT WT ATT WT MG TOT MC CAT AST CCT TCT GAT 1381 CAT TTA AGG TCT TAT GTT AAT ATG GCA CAT GCA TTT GGA ACA GAC ACT TTA ATT OCT TTA
220 CAT TTA AGO TCT TAT GTT AAT ATT GCA CAT GCA TTT GGA ACA GAT ACT TTA ATT OCT TTA
Gln Trp Leu Asn Val Asn Ash Trp Ser As, Asp Arg Met Pro Ile Asp Se, Ile Gly Phe Ile
601 CM TOG TTA MT GTT MI MC TOG TCA MT GAT AGA ATG CCA ATC GAT TCA ATT GGA TIT 500
240 Val Lys Ser Tyr Tyr Gly Leu Trp Tyr Glu Asn Asn Phe Glu Se r Lys Tyr Ser Ile Lys
Asp Leu Gly Leu As, Thr Thr Gln Pro Tyr Ile Ile Assn Asp Thr Phe Lys Ile Gly Ser 1441 GTT AAA TCT TAT TAT GGA TTA TOO TAT GM MT MT TTT GM AGT AAA TAT TCA ATT MA
661 GAT TTA GGA CTT MT ACA ACG CM CCA TAC ATT ATT AAT GAT ACA TTT AM ATA GGA TCA GTT AAA TCT TAT TAT GGG CTA TOG TAT GM MT MT TAT GM QGT GAG TAT TCA ATT AAG
260 Tyr Gly Glu
Pro Phe Gly Gly Met Ile Tyr Leu Arg Set
Asp Th . Th . Phe Thr Asn Ser Phe Tyr Val 520
121 CCA TTT GGA GOT ATG ATT TAT TTA AGA TCT GAT ACA ACA TTT ACA MT TCA TTT TAT GTC Arg Asp Se[ Thr Ser Al, Phe Cys Leu Leu Ale Ala Leu Val The Lys Arg Asp Thr Arg
280 1501 AGA GAT TCT ACC TCT WT TIC TOT TTG TTA WT GCA TTA GTT ACA AM AGA GAT ACT AGA
Thr Phe Ser As, Val Gly Arg Al
.
Pro Ile Ile AS, Tyr Asn Ile Thr Thr AS, Glu Glu AGA GAT TCA ACT TCA OCT TIC TOT TTG TTA WT GCA ATT OCT ACA AAA AGA GAT ACT AGA
781 ACA TTC AGT MT GTT GGA AGA GCT CCA ATT ATT MT TAT MT ATT ACA ACG MI GM GM Ile Al .
300 540
Trp As, Ser Val Lou Acg Asn Al
.
Pro Gly Asn Val Ala Glu Ile Arg Thr Pro Gly AS. Tyr Leu Cys Ser Leu Phe Lys Tyr Asp Ile Gln Ser Asn Val Sec GI, Al, Ile Lys AS .
841 TOG AAT AGT GTT TTA AGA MT GCA CCA GGA MT GTT WA GM ATC AGA ACA CCA GGA MT 1561 TAC TTA TGT TCT CIA TTT AM TAT GAT ATA CM TCA MT GTT TCA GM GCA ATT AM MT
320 TAI TTA TOT TCT CTM TTT AM TAC GAT ATA CM CAA MI (TIT TCA GM GCA ATT MA AAC
Arg Leu Val Lou Thr Sec Arg Asn Ile Acg Set Leu Glu Asp Ala Gln Tyr Ile Ser Asp Gln
901 AGA CTT GTA CTT ACT TCA AGA MT ATT AGA AGT TTG GM GAT WA CM TAT ATT AGT GAT 560
340 Met AS, Tyr Pro Thr Tyr Tyr Pro Phe Phe As, Leu Tyr Ala Met Ser Tyr As, Gly Asn
Phe Trp Leu Lys Ala Ile Se, Ile Ser Aan Tyr Al a Val The Leu Glu Asn Ile Pro Ile 1621 ATG MT TAT CCA ACT TAT TAT CCA TIC TIC MC CTC TAT GCC ATG AGT TAT MT GGA MT
961 TIC TOG TTA AM GCA ATT AGT ATT TCT MT TAT OCT GTT ACA CTT GM MT ATT CCA ATT ATG MT TAT CCA ACT TAT TAT CCA TIC TIC AAM GTT TAT OCT ATG AGT TAC MT GGA MT
CCA ATC Val
800
Phe Ile Acg Ile Gly Tyr Cys Tyr His Gly Thr G1u Glu Ser So' Val Asp Val So, Lys
560 2341 TIT ATT AGA ATA GGA TAT TGT TAT CAT GGA ACA GM GM TCA AGT GTT GAT GTT TCT AM
Tyr Tyr Gly Arg Pro Tyr Lys Ile Pro Tyr Gly Acq The Arg Leu Asn Phe Thr Al, Thr TIT ATT AGA ATA GGQ TAT TOT TAT CAA GGA ACA GM CAG TCT AGT GTT AAT GTT TCC AAA
1681 TAC TAT GGA AGA CCC TAT AM ATT CCA TAT GGA AGA ACT AGA TTG MT TTC ACT GCA ACT GIn Gln Asn
TAT TAT GGA AGA ACA TAT AM ATT CCA TAT GOT ACA ACT AGA TTG MT III ACA GCA ACC 820
Thr Thr Cys Ser Val Ser Asp Ile Gly So, Sec Mat Val Leu Iwsn Glu Lys Val Lys Thr Gly
Al
.
600 2401 TG C AGT GTA TCA GAT ATT GOA AGC TCT ATG GTT CTT MT GM AM GTT AAA ACA GGA GCA
Thr Ala Ile Asp Pro Lys Al
.
Thr Sec Val Bar Tyr Thr Ile Lys Ser Gly Leu Thr Lys TOM AGT WA TTA GAT ATT GGA AGC
1741 ACT OCT ATA GAT CCA AAA GCA ACT AGT GTT AGT TAT ACT ATT ASO TCT GGA TTA ACT AAA Gly Leu
ACT OCT ATA GAT CCA AGM GCA ACT AGT GTT AGT CAT ACC ATT AAA TCT GOT TTA ACT AAA 840
Se, His Lys Glu Pro Glu Phe Gin Ile Pro Pro Ile Lys Tyr Ser Arg Pro Thr Arg Phe Leu Thr
620 2461 AAA GM CCA GM TIC CM ATT C CA CCA ATT AM TAT AGC AGA CCA ACA CGT TIC TTA ACT
Gly Lys Lau Glu Arg Val Glu Asp As, Val Tyr Asp Tyr Thr Pro Phe Phe Gly Ile Glu 860
1001 GOA AM TTA GM CGA GTT GM GAC MT WT TAT GAC TAT ACA CCA TIC TTT GGA ATA GM Asn Al, Tyr Arg Thr Ile Pro Lys Cys I.S . Asn Gly Asp Asp All Cys Ser Ile Lys Cys
GGA AAG TTA GM CM GTT GM GM MT GTT TAT GAT TAT ACA CCA SAC TTT GGA GCA GAT 2521 AAT GCA TAT AGA ACT ATT CCA AM TOT TTG MT GOT GAC GAT WT TOT TCT ATT AAA TGT
Gln Glu AS . Al. Asp
640
800
Leu Ser Leu Leu Pro Leu Lys His Asp Asp Ser Ser Lys Cys Ser Asn Met Phe Asp Asp
Glu As, Asp Thr Phe Val Leu AS, Ile Alp Cys Val Val As, Gly Glu Lys Val His Ile 2581 CTC TCC TTA TTA CCA CTT AM CAT GAT GAT TCA AGT AM TOT TCT MT ATG TTT GAT GAT
1061 GM AAT GAT ACA TTT GTT TTA AAT ATT GAT TOT GTT GTT MT GGA GM AAA GTA CAT ATC 900
GM MT GAT ACT TTT GTT TTG MT ATT GAT TOT ATC GTT MT GGA GM AAI, GTA CAT ATI As n Tyr Sec Thr Met Tyr His Ser Arg Trp Thr Gly Gln Gly Thr Thr Phe Pro Val Asn
Ile
2641 MT TAT TCT ACT ATG TAT CAT TCA AGA TOG ACT GGA CM GGA ACT ACT TIC CCA GTT MT
660
Glu Gin Glu Gly Thr Phe Glu Leu Asp Pro His Gln Val Glu Tyr Glu Val Tyr Lys Asp
920
Tyr Thr Phe Glu Phe Ser Glu As, Val Thr Phe AS, As, Leu Tyr Val His His Arg Arg
1921 GM CM GM GGA ACA TTT GM ITA GAT CCA CAT CM GTA GM TAT GM GTT TAT AM GAT 2701 TAT ACA TTT GM TIC TCA GM MT GTA ACA TTT AAT -T CTT TAT GTT CAT CAT AGA AGA
GM CM GAC GGA ACA TTT GTA CTA GAC CCA CAT CM GTA GAG TAT GM GTT TAT AM GAT 940
Pro Glu Asp Ser Tcp Gly Tyr Phe Glu Met Phe Val Lys Se, Pro Glu Thr Gly Glu Met Asp
680
2761 CCT GM GAT TCA TOG GGA TAC TTT GM ATG TTT GTT AM TCT CCA GM ACA GGA GM ATG
V81 Gin Th[ Arq Aep Met Al, Gln Al, Ile Asn Ile Ile Gln All Lys Thr Arg As. Asp 960
Glu Leu Lou Glu Lys Tyr Lys His Pro Lys $er Thr Thr Thr Glu Leu Asn Phe Glh Lys 1901 GTT CM ACA AGA GAT ATG GCA CM OCT ATT MT ATT ATT CAG MT AM ACT CGT MT GAT 2821 GAG TTA TTA GM MA TAT MG CAT CCA MG TCT ACT ACA ACA GM CTT MT TIC CM AM GTT AAA ACA AAA GAT ATG GAA CM WT CTT AAT ACT ATT CAG MT AAA ACT ICT MT MAT
980 Lys Lys Glu Leu Th. Ser Tyr Leu Val Th . Thr Asp Acg Val Gln Phe Ile Val Ty[ Ash Ash Ser As, Gly Gly AS, Tyr 700
Thr Gly Arg Ala Ser Phe Phe Gly Ile Gly Thr Tyr AS, Asp Gly Ser Met Gln Ser Met
2081 TTA GTT ACA ACT GAT COT OTC CM TTT ATT GTC TAT MT MT TCA MT GOT GGA MT TAT
2041 ACA WA AGO WT TCA TTC TTT GGA ATT GGA ACA TAT MT GAT GGA TCA ATG CM TCA ATG 1000
Val AS, Val Val Glu Lou Se r Phe Asn Ile Lys Glu Thr Phe Lys As, Tyr Thr As, Ser ACA WT. ACG ICT ACA TIC TTT GGA ATT GGA AAI TAT OAT GAT GGA ACA ATG CM TCA ATG 2941 GTC MI GTT GTA GM TTG TCT TIC MT ATT MG GM ACC TTT MG MT TAT ACA MT ICA Thr Sex Thr Asn Asp Thr
1020
720 Phe Gly Pro Lys Ile Lys Ser Thr Gly Phe Lys Lys Val Thr Thr Pro Gly Ala Ser Gly Leu Val Glu Lys Gly Lys Leu Ile Val Pro Lys Ser Gly Tyr Tyr Thr Leu Phe Met Lys 3001 TTT GGA CCA MG ATT AAA AGT ACT GGA ITT MG MA GTT ACT ACA CCA GOT OCT TCA GGA 2101 TTA GTA GM AM GOT AAA TTG ATA GTT CCA MA TCT GGA TAT TAT ACA TTG TTT ATG MA
1090 TTA GTA GM MA WT AM CTG ATA GTT CCA ACA TCA GGA TAT TAT ACA TTG TTT ATG AM
Leu Thr
Gly Tyr Leu Ala Val Aan Glu Lys Glu Gly Glu Gly Sec Leu Cys Phe Lys Ala Lys Val
740
3061 GGA TAT CTT GCA GTA MT GM MG GM GGA GM GGA TCA CTT TOT TIC AM OCT AM GTC
Ala Asp Aep Leu Gly Arg Leu Leu Leu Asn Ile The Gly G1u Tyr G1u Gln Leu Leu Asp
1
060 Thr Lys Phe Gly La, Tyr Gly Tyr Arg Lys Thr Thr Sec Gly Lys Phe Arg Val Thr Ile 2161 GCA GAT GAT TTA GGA AGA TTG TTA TTG MI ATT ACT GGA GAG TAT GM CM TTA TTA GAT 3121 ACT MA TIC GOT CTT TAT GGA TAT AGA AM ACA ACA TCT GGA MG TTT AGA GTT ACA ATT
GCA OAT GAT TTA GGA AGG TTG TTG TTA MT GTT AAT GGA GAG TAT GM CM TTA TTA AAT 1080
Val AS . A
N
Asp Ser Gln Pro Gly Glu Val Thr Ser Gln So, Tyr Phe Ser Asp Se . Glu Arg Thr
Lou 760 3
181
GAC TCA CM CCA WT GM GTT ACT AGC CM AGT TAT TIC TCT GAC TCT GM CGA ACT ITG
Val Lys Thr Tyr Leu Gly Gly Tyr Ser Lys Thr Leu Asn Gly So, Tyr Ala Thr Val Lys 1100
2221 GTT MA ACA TAT CTT GGA WT TAT TCA MA ACT CTT MT GGA AGT TAT GCA ACT GTA AM Phe Tyr Ala His Thr Phe Asp Glu Thr Glu Ala All Lys Vel His Asn Ile Cys Met Glu
GTT MA ACA TAT CTT GGA WT TAT TCA AM ACT ATC AAI GGA ACT TAT GCA ACT GTA AM 3241 TTC TAT OCT CAT ACT TTT GAT GM ACT GM GCA MC AM GTT CAT MC ATT TGT ATG GM
Ile Thr 1114
780 Val Val Glu Gly Thr Val Asn is, Asp Ile Ile Gly Set Ser ---
Leu Glu Lys Asp Val Gly Tyr Pro Phe 11 . Leu Tyr Asn Leu Asn Thr Gly Gly Gln Gly 3301 GTT GTT GM GGA ACA GTT MI CTT GAT ATC ATT GOT TCT TCT TM acgttaattgaagatattt
2281 TTG GM AM GAT GIG GGA TAT CCA TTT ATT CTT TAT MT TTG MT ACT GGA GGA CM GGA
TTA GAG AM GAT ACT CAA TAT CCA TTT ATT CTT TAC AAC QTA MT ACT GGA GGA CM GGA 3444
Thr Glu Leu 3365 cattttaaatoatgtagtgttattttaattttattgagaaaattttgagtctatttcattacatattgaatcatgattg
gaagctataaataagetatagaaatataaeagaatg 360
Thr Leu AS, Phe Asp Gln Atg Val Asp Ala Gly Ala Ala Val Ala Tyr Val Gly Arg Trp
ttaaaaatgeaeecaaacataaaaaataagtgtotttaaagtgtttttaaaaaaactaatt-ATTCATAMTTMAGTT 1021 ACA TTA AAC ITT GAT CM AGA GTT GAT GCA GGA OCT WT GTT GCA TAT GTA GGA COT TOG
20 ACA TTA AAC TTT GAT CM AGA GTT GAT GCT GGA GCT OCT GTT GCA TIT GTA GGA AGA TOO
Met Leu Gly Ser Lys Ser Ile Ile Ala Val Val Ala Ile Ala Ser Al, Ile Val Thr Gly Phe
1 ATG TTA GOT TCT MA AGC ATT ATT OCT GTT GIG OCT ATA OCT TCT GCA ATA OTC ACA GGA 380
40 Phe Thr Gin Asn Pro Ser Asp Trp Ala Ala Ala Cys Val Gly Lys Asp Gly Leu Ile Asn
Va1 VaI Val Ile Val Val Val Val Thr Leu Ser Val Val Leu Thr Arg Set Set Val Lys 1081 TIT ACT CM MC CCA TCC GAT TOG GCA GCT GCA TOT GTT GOT MA GAT GGA TTA ATA AAT
61 GTA GTT GTT ATA GTT GTT GTT GTT ACA CTT TCT GTG GTT TTA ACA AGA AGT AGT GTT AM TIT ACT CM CAC CCA TCT GAC TOO GCG ICT GGA TGC GTT AAC AM GM AGA TTA ATA MT
60 His So . Gly AS . Arg
Asp Thr Asn Ser Ile Tyr Val Pro Asp Val Ile Thr Asn Asp Pro Gln Met Thr Ash Glu 400
121 GAC ACC MC TCT ATT TAT GTT CCT GAT GTT ATT ACT MC GAC CCA CM ATG ACA MI GM Tyr Gly AS, Trp Gly Pro is, His G1u Met AS, His His Met Gln Gly Th . Tyr Leu Lys
80 1- TAT GGA MT TOO GGA CCA TTA CAT GM ATG MT CAT CAT ATG CM GGA ACT TAT TTA AM
Met Asp Thr Leu Glu Val Ile So, So, Ser Lys Phe Ser Gly Thr Lys Pro Lys Glu Trp TCT GGA AAT TOG GGA CCA TTA CAT GM ATG AAT CAT CAC ATG CM GGA ACT TAT TTA AGA
181 ATG GAT ACA TTA GAG GTT ATT TCT TCT TCA AM ITT AGT GGA ACA MA CCA MA GM TOG Ser Arg
100 420
Thr Met Lys Tyr Thr Lys Tyr Pro Tyr Trp Thr Cys Gly Leu Thr Phe Thr AS, Glu Glu Gly Gly Asn Trp Gly Ile Ser Asn Pro Gly Glu Glu Thr Asn AS . Val Met Thr Ser Ile
241 ACT ATG AM TAT ACA MA TAT CCT TAT TOG ACA TGT GGA CTT ACA TTT ACT MT GAG GM 1201 GOA GGA MT TOG GOT ATT AGT MT CCA GGA GM GM ACT MT MT GTT ATG ACA TCA ATT
120 GGA GGA MI GOO GOT ATC AAA GAA CCA GGA GM GM ACT MT MI GTT ATG ACA TCA ATT
Lys Gln Asn Ile Val As, Glu As, Lys Glu Tyr Met Asn Set Lou Leu Gln Leu Ile As, Gly Lys Glu
301 AM CM MT ATT GTT MT GM MT MG GM TAT ATG MC TCA TTA TTA CM CTT ATT MT 440Figure 4.
￿
Transfer blot of E. histo-
lytica HM1:IMSS RNA probed with
cDNA clone XcM17 indicates a
single hybridizing band migrating at
-3 kb. Hybridization conditions
were 50% formamide, 0.2x SSC,
42°C . Autoradiography shown re-
quired a 72-h exposure .
with Bg1II andEcoRV in single and double digests, was probed
with BamHI-Bg1II, Bg1II-EcoRV, and EcoRV fragments of
AcM17, only unique restriction fragments hybridized with
each probe (data not shown) . Furthermore, the nucleotide
sequence of both genomic clones and the cDNA clone is
identical .
Detection ofSequences Related to GeneM17 in Nonpathogenic
E . Histolytica and Mapping ofRFLPs. Western blot anal-
ysis suggested that the 125-kD antigen or a closely related
antigen that shared the epitope recognized by poly- and mono-
clonal antisera was found in both pathogenic and nonpatho-
genicE. histolytica isolates as well asE. histolytica-like Laredo.
By Southern blot analysis, even under low stringency hybrid-
ization and wash conditions (25% formamide, 2 x SSC,
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37°C) sequences related to M17 were difficult to detect in
nonpathogenic E . histolytica isolates and E. histolytica-like
Laredo (data not shown) . To confirm the presence of a closely
related gene in nonpathogenic amoebae, two fragments span-
ning most of the sequence contained within thecDNA clone
XcM17 were amplified in a PCR using oligonucleotide pairs
SRO19/SRO22, and SRO18/SRO21 as primers on genomic
templateDNA derived from nonpathogenic isolate REF 291 .
By nucleotide sequence analysis of the two subcloned PCR
amplification products, REF 291 had 145 nucleotide substi-
tutions over 1410 residues (10.3%) as compared with the se-
quence ofAcM17(HM1:IMSS) (Fig. 3) . These substitutions
result in 57 amino acid differences per 470 residues (12.1%) .
A computer search of published protein sequences with the
entire 3,345 by M17 gene sequence revealed that the internal
gene fragment represented by the XcM17 insert encoded a
protein sequence similar to that deduced for a DNA frag-
ment isolated from nonpathogenic and pathogenic strains of
E. histolytica by Tannich et al. (29) and proposed by these
authors as a potential diagnostic probe for strain differentia-
tion . Specifically, whenwe compared the amino acid sequences
of Tannich et al . with that ofXcM17 we detected five substi-
tutions between pathogenic HM1:IMSS isolates (1%) (Fig.
6) . As the nucleotide sequence of the DNA fragment was
not published by Tannich et al ., we infer from the amino
acid sequence that at least three of these five differences be-
tween the E. histolytica HMI:IMSS laboratory strains must
have arisen from more than one nucleotide substitution and
are therefore unlikely to represent cDNA synthesis or se-
quencing artifacts. When the 470 amino acid sequence de-
rived from thePCR product of nonpathogenic isolate REP291
was compared with isolate SAW 1734 (29), six amino acid
substitutions (1.3%) were detected (Fig. 6) . Over. the same
470 amino acids, 61 amino acid residues (12.9%) differamong
the pathogenicHMI:IMSS (29) and nonpathogenicSAW 1734
(29) strains (Fig . 6) . Overall there are 65 variable residues
over a stretch of 470 amino acids (13.8%) when these four
isolates were compared (Fig. 6) .
As the partialM17 amino acid sequences of nonpathogenic
strainsSAW 1734 (29) and REF 291 were significantly more
similar to one another than to their pathogenic counterparts,
PCR amplification of the same gene fragments from six ad-
ditional strains was undertaken to examine the possibility of
defining RFLPs that could reliably differentiate pathogenic
from nonpathogenic amoebal isolates. Using oligonucleotide
primers SRO19, SR022, SRO18, and SR021, PCR prod-
ucts of the same size were amplified from genomic DNA
of strains SD116, SD4, Nos . 43, 44, 46, and HK9 . Based
An Immuno-dominant Variable Surface Antigen from Entatnoeba histolytic .
Figure 5.
￿
Alignment of the 5' flanking se-
quences from genes M17, actin'(36), 1(44) and
ferredoxin (45); a likely Goldberg-Hogness con-
sensus sequence at -29, -31, -32, respectively,
is boxed and in bold face . The 5' end of the
mRNA is in bold face and italics and sequence
similarities around the cap site are boxed and
shaded .on our nucleotide sequence of these fragments from HM1:
IMSS and REF291, we predicted that restriction endonucleases
EcoRV, SspI, PvuII, AccI, and HincII among others would
cleave the PCR products into restriction fragments which
might be expected to correlate with the pathogenic or non-
pathogenic phenotype of the isolate . An example of such an
analysis with EcoRV and SspI is presented in Fig. 7 . A re-
striction site for EcoRV is absent in nonpathogenic No. 43,
No. 44, and REF291 but present in nonpathogenic SD116
and Laredo as well as pathogenic HMMMSS, HK9, SD4,
andNo. 46 (Fig. 7) . Digestion with restriction endonuclease
SspI shows a distinct pattern for pathogenic (HM1:IMSS,
HK9, SD4, 46) versus non-pathogenic (No. 43, No. 44,
SD116, REF291) strains with the exception ofE. histolytica-like
Laredo, which would appear pathogenic by this criterion (Fig.
7) . Similarly, restriction with AccI distinguishes pathogenic
from nonpathogenic isolates with the exception of Laredo,
which appears to have an additional restriction site for the
enzyme. HincII digestion shows the same restriction frag-
ments in nonpathogenic isolates No . 43, No . 44, andREF291
and pathogenic isolate SD4 but no restriction sites in com-
mensal Laredo and pathogenic isolates No. 46, HMI:IMSS,
and HK9 .
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Discussion
It has long been known that amoebiasis is a spectral disease,
asymptomatic infections with "nonpathogenic" amoebae and
life-threatening infections with "pathogenic" amoebae defining
opposite ends of the spectrum . With the availability ofeffec-
tive treatment regimens, early diagnosis is crucial for the
prevention ofdisease and transmission. However, much con-
troversy has centered on benefits and drawbacks of initiating
therapy in asymptomatic infections . Thus, recent investiga-
tions have focussed on a molecular genetic analysis of viru-
lence and the definition of marker molecules that have high
predictive value and can be applied in a clinically feasible
fashion.
We have identified a variable, immunodominant 125-kD
surface antigen inE. histolytica HM1:IMSS. The amino acid
sequence inferred from the nucleotide sequence of the coding
region of the 125-kD antigen is unusual with respect to its
high Asn (90 - 8.2%), Tyr (70 = 6.3%), and hydroxyl
amino acid residue (Ser, 85 = 7.6% ; Thr, 90 = 8.1%) con-
tent . While a total of 17 N-linked glycosylation sites sug-
gests that the 125-kD antigen may be glycosylated, Western
blot analysis shows that this antigen migrates as a compact
band on SDS-PAGE . A distinctly hydrophobic NHZ-ter-
Figure 6 .
￿
Alignment of the
amino acid sequences inferred
from nucleotide sequences of
cDNA and genomic clones
(HMI:IMSS') and of PCP, am-
plification products (REF291')
with those published by Tannich
et al . (HM1:IMSS#, SAW 1734#)
(29) . Conserved amino acids are
shaded, variable residues differen-
tiating pathogenic from nonpath-
ogenic isolates are in bold face,
and additional variable residues
are in plain text .Figure 7.
￿
Restriction endonuclease (EcoRV lower case letters, Sspl
capital letters) digests of PCR products generated by amplification of
genomic DNA from E. histolytic, isolates/strains using oligonucleotide
primers SRO 18 + 21 and SR019 + 22. (alA) No. 43, (blB) No.
44, (clC) SD116, (d/D) REF291, (WE) E. histolytic,-like Laredo,
(flF) No. 46, (glG) HK9, (h/H) = HMMMSS.
minal region of 35 amino acids may serve as anchor or signal
sequence. Compared with known prokaryotic and eukaryotic
signal sequences this region contains an unusually long (20
amino acids) NH2-terminal (n) region with a single posi-
tively charged residue, an 8 amino acid long hydrophobic core
(h) region and a 7 amino acid long polar COOH-terminal
(c) region with an amino acid composition similar to those
seen in other signal sequences (46) . By extrapolation this would
imply that the antigen is either a peripheral membrane pro-
tein or it may be anchored in the membrane by other means
such as a glycophospholipid anchor. Alternatively, the hy-
drophobic NH2-terminal itself may serve to anchor the an-
tigen in the membrane with the COON-terminal externally
exposed as no additional trans membrane domains could be
discerned. From searches ofprotein and nucleic acid sequence
data banks, a small domain was identified sharing sequence
similarity with the (3 chain of thehuman fibronectin receptor,
the (3-1 chain of the mouse integrin, and band 3 precursor
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of the chicken integrin (Fig. 8) . However intriguing, the func-
tional significance of this similarity will need to be assessed
by generation of antibodies to this domain for use in attach-
ment or invasion assays .
Tannich et al. (29) had reported a sequence of 1.9 kb that
differed substantially between pathogenic and nonpathogenic
E. histolytic, and also suggested thatRFLPs in this gene frag-
ment would allow the differentiation ofpathogenic from non-
pathogenicE. histolytic, . Examination of the Tannich sequence
revealed that it was derived from an internal fragment ofM17,
the gene sequenced in its entirety in this paper. Whilehuman
sera andmAb FA7 demonstrated the presence of the 125-kD
antigen in a number ofnonpathogenic and pathogenic amoebal
isolates (Fig . 1), DNA hybridization data with the XcM17
probe suggested that there were regions ofsubstantial sequence
variability in other portions of this molecule . For this reason,
fragments of this antigen within a variable sequence region
were amplified by the PCR to search for RFLPs that cor-
related with phenotype. If in fact RFLPs could be used to
differentiate pathogenic from nonpathogenic strains, then in
combination with FA7, PCR could provide a potent diag-
nostic protocol.
Based on the nucleotide sequence differences of strains
HM1:IMSS and REF291, presented in Fig. 3, five restriction
endonucleases were chosen that should have yielded RFLPs
which correlate with the pathogenic and nonpathogenic
phenotype ofthe isolate from which the PCR fragments were
derived . PCR fragments from four fresh polyxenic nonpatho-
genic isolates of zymodeme I (SD116, No . 43, No. 44) or
III (REF291), from axenized Laredo, from two fresh poly-
xenic pathogenic isolates (SD4, No. 46) ofzymodeme II and
two axenized established pathogenic laboratory strains (HM1 :
IMSS, HK9) ofzymodeme II were subjected to this analysis .
Our results provide strong evidence that the M17 antigen
is a highly variable protein and that distinct sets of amino
acid substitutions exist in pathogenic versus nonpathogenic
strains of Entamoeba . These differences provide the basis for
RFLPs which, in the limited sampling of this study, are cor-
related with pathogenic and nonpathogenic isolates . The ex-
ception to this correlation is theE. histolytic,-like Laredo strain
that is often used as a prototype nonpathogen in laboratory
studies . Although Laredo was first isolated as ahuman com-
mensal it appears morphologically more like free-living
amoebae and belongs to an unusual zymodeme that is rarely
found in patient isolates. Thus, Laredo's RFLP pattern may
not preclude the use of this criterion in the clinical context .
An Immuno-dominant Variable Surface Antigen from Entamoeba histolytic,
Figure 8 .
￿
Similarity of a small
region of the amino acid sequence
inferred from the M17 nucleotide
sequence to the /3 chain of the
human fibronectin receptor, the
band 3 precursor of the chick inte-
grin, and the 0-chain of the
mouse integrin .Given the rather limited sample size tested here, it is, how-
ever, noteworthy that none ofthe pathogenicisolates revealed
a nonpathogenic RFLP pattern in this analysis.
While gene fragments from HM1:IMSS analyzed in these
experiments were derived from the same original isolate, they
have been propagated in different laboratories for some time.
The extent of sequence differences indicates that a low de-
gree of variation probably occurs within this gene family in
the absence of selective pressure by the host immune system.
Although the position and nature of most of the amino acid
substitutions are conserved, it is clear that overall extensive
interstrain variability and the modest intrastrain variability
among strains with the same phenotype necessitate that RFLPs
be validated on large numbers of amoebal isolates. Zymo-
deme characterization and the use of additional diagnostic
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